This week, we will discuss intermittent hemodialysis versus continuous hemodialysis for AKI in the ICU (ICRAKI study)
Day 3 : yet another IgA trial, and we are back with some flozin news: in ADPKD, their effect on hemoglobin, and on BP (with finerenone)
Day 2 was less exciting: we cover 1 IgA trial (Ravulizumab) along with another calcimimetic, and a pentoxifylline meta-analysis.
Day of Kidney Week 2026. The NephJC crew discusses 6 studies, including some blockbustr IgA news.
This week, we will discuss whether decreased donor transplantation improves mortality in all patients. In this target trial emulation standard donor, extended donor, donation after brain death and donation after cardiac death outcomes are compared across age groups with different co-morbid conditions.
¡La Marea de Semaglutida llegó a la Enfermedad Renal Crónica!
Del monstruo de Gila al estudio FLOW.
Para ello, veamos el hermoso resumen visual realizado por la pasante de NephEdC, Anjana Gopal, traducido por Milagros Flores.
‘FLOW’ing with the Semaglu’TIDE’!
Check the beautiful visual abstract made by NephEdC intern Anjana Gopal, with an appearance of the Gila monster as well.
